Metagenomi Therapeutics Free Cash Flow 2022-2026 | MGX
Metagenomi Therapeutics free cash flow from 2022 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Metagenomi Therapeutics Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | -112.19 |
| 2023 | -101.22 |
| 2022 | 15.75 |
| 2021 | 21.35 |
| Metagenomi Therapeutics Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | -65.80 |
| 2025-06-30 | -44.47 |
| 2025-03-31 | -23.13 |
| 2024-12-31 | -112.19 |
| 2024-09-30 | -85.58 |
| 2024-06-30 | -57.74 |
| 2024-03-31 | -30.77 |
| 2023-12-31 | -101.22 |
| 2023-09-30 | -78.89 |
| 2023-06-30 | -52.91 |
| 2023-03-31 | -23.66 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |